Floatz logo

Ibrutinib

Prolymphocytic Leukemia

Explore 21 assets in Prolymphocytic Leukemia →
Floatz Rating
B63/100
Confidence
Indicative
v0.2
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT02662296CT.gov
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
—Withdrawn———
NCT02303392CT.gov
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
—Completed———
NCT02007044CT.gov
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
—Active Not Recruiting———
NCT01589302CT.gov
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
—Active Not Recruiting———
NCT01217749CT.gov
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Prolymphocytic Leukemia

AssetSponsorPhaseRating
Ibrutinib (this asset)Fred Hutchinson Cancer CenterP2B · 63
CyclophosphamideCenter for International Blood and Marrow Transplant ResearchP2BBB
FludarabineCenter for International Blood and Marrow Transplant ResearchP3BB
NivestimCenter for International Blood and Marrow Transplant ResearchP2BB
Cyclosporin AFred Hutchinson Cancer CenterP3BB
TacrolimusCenter for International Blood and Marrow Transplant ResearchP2BB
BusulfanumCenter for International Blood and Marrow Transplant ResearchP2BB
MelphalanCenter for International Blood and Marrow Transplant ResearchP2BB
RituximabAcerta Pharma BVP2B

+42 more in the Prolymphocytic Leukemia cohort

Other indications for Ibrutinib

IndicationSponsorPhaseRating
Lymphoid Leukemia—P4BBB · 72
Waldenstrom Macroglobulinemia—P4BB · 70
B-Cell Chronic Lymphocytic Leukemia—P4BB · 70

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Ibrutinib in Prolymphocytic Leukemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 13, 2026.
https://terminal.floatz.ai/assets/ibrutinib-prolymphocytic-leukemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →